Given the success of PRAX-628 in the recent study, how does PRAX-628 differentiate from existing epilepsy medications, especially in terms of its mechanism targeting sodium channel hyperexcitability?

Could you elaborate on the significance of the complete and partial response rates observed in the 15 mg and 45 mg cohorts of the PRAX-628 study, and what this implies for its potential use in clinical practice?

In the context of the safety profile consistent with prior studies, what are the key considerations for clinicians when assessing PRAX-628 as a treatment option for epilepsy patients?

How does the pharmacokinetic analysis from the PRAX-628 study support its once-daily dosing regimen, and what advantages does this present for patient compliance and overall management of epilepsy?

Considering the study included patients on background anti-seizure medications, how does PRAX-628 perform in combination therapy compared to monotherapy in epilepsy management?

With the planned efficacy study in focal onset epilepsy, what are the expected outcomes, and how could PRAX-628 change the current treatment landscape for this specific type of epilepsy?

How does the quantitative EEG data from the study enhance our understanding of PRAX-628's pharmacodynamic effect, and what are the implications for its clinical application?

What are the anticipated next steps for PRAX-628 following this study, and what should the medical community and patients expect in terms of its development and availability?